Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab to reduce brain injury after aneurysmal subarachnoid hemorrhage
2017-004307-51Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of eculizumab in subarachnoid hemorrhage (SAH), sponsored by University Medical Center Utrecht. Primary endpoint: Biological effectivity (C5a concentration in CSF). Started Jan 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2017-004307-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004307-51.